益气温阳方对乳腺癌内分泌治疗患者无病生存期及生活质量的影响

The effect of Yiqi Wenyang formula on the disease free survival and life quality of the patients with hormonal therapy for breast cancer

目的观察益气温阳方对乳腺癌内分泌治疗患者无病生存期及生活质量的影响。方法选择2010年1月—2013年4月收治的86例乳腺癌术后内分泌治疗患者作为研究对象,随机分为对照组和观察组各43例。对照组给予来曲唑片2.5 mg/次,1次/d,口服治疗;观察组在对照组的基础上联合益气温阳方治疗,1剂/d。治疗6个月后对比两组生活质量及不良反应发生情况,长期随访对比两组患者无病生存期。计量资料组间比较采用t检验,组内比较采用配对t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果随访期内,观察组无病生存期为(2.17±0.42)年,明显长于对照组的(1.52±0.35)年,差异有统计学意义(P<0.05)。观察组复发(转移)率为13.95%,低于对照组的37.21%,差异有统计学意义(P<0.05)。治疗后,观察组总体健康状态评分、症状评分、乳腺癌特异评价评分分别为(371.66±43.26)、(112.38±51.29)、(136.46±61.53)分,均优于治疗前的(175.19±31.49)、(460.73±64.33)、(309.91±70.93)分;对照组治疗后分别为(297.39±41.67)、(199.37±58.45)、(227.91±63.76)分,均优于治疗前的(184.73±32.44)、(451.66±61.78)、(317.69±72.34)分,差异均有统计学意义(均P<0.05)。两组治疗后各评分差异均有统计学意义(均P<0.05)。观察组不良反应评分为(6.31±2.96)分,低于对照组的(11.75±4.31)分,差异有统计学意义(P<0.05)。结论益气温阳方可延长乳腺癌内分泌治疗患者无病生存期,减轻不良反应,提高生活质量。

Objective To observe the affect of disease free survival and life quality of Yiqi Wenyang formula combined with hormonal therapy in the treatment of breast cancer. Methods 86 cases of breast cancer patients receive hormonal therapy after surgery from January 2010 to April 2013 were selected, randomly divided into control group and observation group （n=43）. The patients in control group were treated with letrozole 2.5 mg/eount, 1 count/d, observation group treated with Yiqi Wenyang formula on the basic of control group. The life quality and incidence condition of adverse reaction after 6 months were record and eompared. The disease free survivals of the two groups was compared in long-term follow up. Measurement data was processed by t test, count data by chi square test, P〈0.05 was considered statistically significant. Result The disease free survival of observation group was（2.17 ± 0.42）years, longer than that of control group[（1.52 ± 0.35）years], the difference was statistically significant（P〈0.05）. The relapse （transfer） rate of observation group was 13.95%, lower than control group＇s 37.21%, the difference was statistically significant（P〈0.05）. The overall health score, symptom score, breast cancer specific evaluation score after treatment of observation group were （371.66 ±43.26）,（112.38 ± 51.29）,（136.46 ± 61.53）points, superior to the scores before treatment [（175.19 ± 31.49）, （460.73 ± 64.33）,（309.91 ± 70.93）points], the scores of control group after treatment were （297.39 ± 41.67）,（199.37 ±58.45）, （227.91±63.76）points, superior to the scores before treatment [（184.73 ± 32.44）,（451.66 ± 61.78）,（317.69 ±72.34）points], the dif- ferences were statistically significant （all P〈0.05）. The adverse reaction score of observation group was （6.31± 2.96）points, lower than control group＇s （11.75 ± 4.31 ）points, the differences was statistically significant（P〈0.05）. Conclusion Yiqi Wenyang formula can prolong the disease free survival of breast cancer receipt hormonal therapy, reduce adverse reaction, enhance the quality of life.